Information Provided By: 
Fly News Breaks for September 7, 2016
TNXP
Sep 7, 2016 | 08:34 EDT
Roth Capital analyst Scott Henry downgraded Tonix Pharmaceuticals to Neutral from Buy as he re-evaluates its PTSD program given that it is now the primary lever for the shares after the company reported that Tonmya phase 3 data to treat fibromyalgia did not achieve its primary endpoint. The analyst also lowered his price target on the shares to $1.25 from $7.5.
News For TNXP From the Last 2 Days
There are no results for your query TNXP
